Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Impact of CD58 Mutations on CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma: Clinical Insights and Therapeutic Potential

Bian Wei, Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Qinlong Zheng, Biping Deng, Zhonghua Fu, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 6549.

https://doi.org/10.1182/blood-2024-206676

Published: 2024

Journal Articles

Utilizing BTK Inhibitors for Maintenance and Long-Term Control Following CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma

Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Zhonghua Fu, Biping Deng, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 6183.

https://doi.org/10.1182/blood-2024-202415

Published: 2024

Journal Articles

The Clinical Value of Prognostic Nutritional Index in CAR-T Therapy for Patients with Malignant Lymphoma

Na Zhang, Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Zhonghua Fu, Haifeng Wu, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 1745.

https://doi.org/10.1182/blood-2024-202403

Published: 2024

Journal Articles

Retrospective Comparison of the Roles of Tocilizumab and Siltuximab in the Management of Toxicity in CAR-T Cell Therapy for Relapsed/Refractory B-NHL

Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Zhonghua Fu, Biping Deng, Chen Chen, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 7247.

https://doi.org/10.1182/blood-2024-201274

Published: 2024

Journal Articles

Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy

Lixia Ma, Rui Liu, Fan Yang, Yuelu Guo, Yimeng Dou, Biping Deng, Zhonghua Fu, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2024-200523

Published: 2024

Journal Articles

Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Fan Yang, Rui Liu, Zhonghua Fu, Yuelu Guo, Lixia Ma, Hui SHI, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 3079.

https://doi.org/10.1182/blood-2024-202286

Published: 2024

Journal Articles

Inhibition of CDC20 Suppressed the Development and Progression of Mantle Cell Lymphoma

Yingtong Chen, Ping Yang, Jing Wang, Shuang Gao, Xiaoyan Ke, Hongmei Jing

Blood (2023) 142 (Supplement 1): 4416.

https://doi.org/10.1182/blood-2023-183096

Published: 2023

Journal Articles

Efficacy and Safety of Autologous Stem Cell Transplantation Combined with Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Refractory/Relapsed B-Cell Lymphoma

Lixia Ma, Xiaoyan Ke, Kai HU

Blood (2023) 142 (Supplement 1): 3434.

https://doi.org/10.1182/blood-2023-184412

Published: 2023

Journal Articles

Evaluating the Impact of Cryopreservation of PBMCs on CAR-T Therapy Efficacy and Safety in DLBCL Patients: An Informative Approach to Optimize Manufacturing Strategies

Teng Xu, Fan Yang, Rui Liu, Zhonghua Fu, Na Li, Xiaoyan Ke, Shaomei Feng, Biping Deng, Kai Hu

Blood (2023) 142 (Supplement 1): 3513.

https://doi.org/10.1182/blood-2023-185590

Published: 2023

Journal Articles

The Mini-Teddi-R Treatment Demonstrated a High Rate of Remission in Patients with DLBCL Involving the CNS Who Had Previously Been Exposed to BTK Inhibitors

Hui SHI, Kai HU, Xiaoyan Ke

Blood (2023) 142 (Supplement 1): 4507.

https://doi.org/10.1182/blood-2023-184452

Published: 2023

Journal Articles

Efficacy and Safety of Zanubrutinib-Containing Regimens in Patients with Secondary CNS Relapse in Diffuse Large B-Cell Lymphoma

Li Bao, Kai HU, Xiaoyan Ke, Yutong Wang, Mengzhen Wang, Lei Shi, Kai Sun

Blood (2023) 142 (Supplement 1): 6095.

https://doi.org/10.1182/blood-2023-181041

Published: 2023

Journal Articles

A Compilation of Experiences in Utilizing CAR-T Cell Therapy for Richter's Transformation

Shaomei Feng, Teng Xu, Haidi Liu, Peihao Zheng, Lixia Ma, Hui SHI, Tong Wu, Fan Yang, Kai HU, Xiaoyan Ke

Blood (2023) 142 (Supplement 1): 4638.

https://doi.org/10.1182/blood-2023-182797

Published: 2023

Journal Articles

Assessment of Activities of Daily Living (ADL)Scale Can be Used to Predict Overall Survival after CAR-T Cell Therapy in Elderly Patient(over 70 years of age) with Refractory/Relapsed B-Cell Lymphoma

Fan Yang, Rui Liu, Teng Xu, Zhonghua Fu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Hui SHI, Lixia Ma, Guoai Su, Biping Deng, Xiaoyan Ke, Kai HU

Blood (2023) 142 (Supplement 1): 6922.

https://doi.org/10.1182/blood-2023-177836

Published: 2023

Journal Articles

CAR T- Cell Therapy Provides an Opportunity for Further Consolidation Treatment for Relapsed or Refractory Adult Burkitt Lymphoma Patients

Rui Liu, Fan Yang, Xiaoyan Ke, Kai HU

Blood (2023) 142 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2023-184692

Published: 2023

Journal Articles

Pharmacokinetics, Safety, and Efficacy of Acalabrutinib in Chinese Patients with Relapsed/Refractory Mantle Cell Lymphoma and Other B-Cell Malignancies: An Open-Label, Multicenter Phase 1/2 Trial

Jun Zhu, Yuqin Song, Jianyong Li, Keshu Zhou, Xiaoyan Ke, Zhen Cai, Huilai Zhang, Tingting Yao, Zhen Xia, Yiqiu Wang, Peiqiong Lai, Xiaofeng Liu

Blood (2022) 140 (Supplement 1): 6496–6497.

https://doi.org/10.1182/blood-2022-157057

Published: 2022

Journal Articles

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Blood (2022) 140 (Supplement 1): 573–576.

https://doi.org/10.1182/blood-2022-163371

Published: 2022

Journal Articles

Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy

Fan Yang, Rui Liu, Teng Xu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Lixia Ma, Hui SHI, Biping Deng, Xiaoyan Ke, Tong Wu, Kai Hu

Blood (2022) 140 (Supplement 1): 10384–10385.

https://doi.org/10.1182/blood-2022-164446

Published: 2022

Journal Articles

Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities

Peihao Zheng, Rui Liu, Teng Xu, Fan Yang, Shaomei Feng, Yuelu Guo, Lixia Ma, Hui Shi, Hongwei Yu, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2022) 140 (Supplement 1): 7548–7549.

https://doi.org/10.1182/blood-2022-168018

Published: 2022

Journal Articles

Secondary Humanized CAR T Cells Salvage Therapy Improves Survival of R/R DLBCL Patients Failed to Murine CD19-CAR T Cells Therapy

Hui SHI, Kai Hu, Xiaoyan Ke, Tong Wu

Blood (2021) 138 (Supplement 1): 4836.

https://doi.org/10.1182/blood-2021-150108

Published: 2021

Journal Articles

Clinical Nursing during CD4-Specific CAR T Cells Treatment for One Mycosis Fungoides Patient Improves Generalized Skin Lesion

NA Zhang, Kai Hu, Xiaoyan Ke

Blood (2021) 138 (Supplement 1): 4974.

https://doi.org/10.1182/blood-2021-151910

Published: 2021

NARROW

Impact of CD58 Mutations on CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma: Clinical Insights and Therapeutic Potential

Utilizing BTK Inhibitors for Maintenance and Long-Term Control Following CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma

The Clinical Value of Prognostic Nutritional Index in CAR-T Therapy for Patients with Malignant Lymphoma

Retrospective Comparison of the Roles of Tocilizumab and Siltuximab in the Management of Toxicity in CAR-T Cell Therapy for Relapsed/Refractory B-NHL

Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy

Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Inhibition of CDC20 Suppressed the Development and Progression of Mantle Cell Lymphoma

Efficacy and Safety of Autologous Stem Cell Transplantation Combined with Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Refractory/Relapsed B-Cell Lymphoma

Evaluating the Impact of Cryopreservation of PBMCs on CAR-T Therapy Efficacy and Safety in DLBCL Patients: An Informative Approach to Optimize Manufacturing Strategies

The Mini-Teddi-R Treatment Demonstrated a High Rate of Remission in Patients with DLBCL Involving the CNS Who Had Previously Been Exposed to BTK Inhibitors

Efficacy and Safety of Zanubrutinib-Containing Regimens in Patients with Secondary CNS Relapse in Diffuse Large B-Cell Lymphoma

A Compilation of Experiences in Utilizing CAR-T Cell Therapy for Richter's Transformation

Assessment of Activities of Daily Living (ADL)Scale Can be Used to Predict Overall Survival after CAR-T Cell Therapy in Elderly Patient(over 70 years of age) with Refractory/Relapsed B-Cell Lymphoma

CAR T- Cell Therapy Provides an Opportunity for Further Consolidation Treatment for Relapsed or Refractory Adult Burkitt Lymphoma Patients

Pharmacokinetics, Safety, and Efficacy of Acalabrutinib in Chinese Patients with Relapsed/Refractory Mantle Cell Lymphoma and Other B-Cell Malignancies: An Open-Label, Multicenter Phase 1/2 Trial

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy

Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities

Secondary Humanized CAR T Cells Salvage Therapy Improves Survival of R/R DLBCL Patients Failed to Murine CD19-CAR T Cells Therapy

Clinical Nursing during CD4-Specific CAR T Cells Treatment for One Mycosis Fungoides Patient Improves Generalized Skin Lesion

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only